| Popis: |
Objective: Cancer is a fatal disease that arises as a result of unregulated growth and spread of malignant cells. According to the reports of World Health Organization (WHO), cancer related deaths are projected to increase in the future with the value of about 13.1 million deaths by the year 2030. In order to control this danger and growing burden, new technologies and therapeutic methods for improving the life quality of cancer patients are being developed. The overall aim of this work was to design of a new anti-cancer drug. Methods: Radiolabeling and quality control studies of PDI-Pyr were carried out by using thin layer radiochromatography. Scintigrams were obtained using a gamma camera (Infinia, GE), which was adjusted to detect g radiations of 131I. Results: Radiolabeling yield of 131I-PDI-Pyr was obtained to be about 97%. Also, the highest uptakes of 131I-PDI-Pyr were observed in the stomach, the liver, the lung and the bladder. Conclusion: The novel PDI-Pyr compound was successfully radiolabeled with 131I using iodogen method for the first time. The preliminary results obtained in this study have indicated that in the case of verification of selective accumulation in some stomach liver, lung and bladder cancer cells, perylene chromophore derivatives promise to be used as new anticancer agents. |
